Favorable trends with DN-101 and docetaxel in androgen-independent prostate cancer. Comment
Publication
, Other
Moul, JW
Published in: Oncology Report
September 1, 2005
Duke Scholars
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
September 1, 2005
Issue
FALL
Start / End Page
54
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Moul, J. W. (2005). Favorable trends with DN-101 and docetaxel in androgen-independent prostate cancer. Comment. Oncology Report.
Moul, J. W. “Favorable trends with DN-101 and docetaxel in androgen-independent prostate cancer. Comment.” Oncology Report, September 1, 2005.
Moul JW. Favorable trends with DN-101 and docetaxel in androgen-independent prostate cancer. Comment. Oncology Report. 2005. p. 54.
Moul, J. W. “Favorable trends with DN-101 and docetaxel in androgen-independent prostate cancer. Comment.” Oncology Report, no. FALL, 1 Sept. 2005, p. 54.
Moul JW. Favorable trends with DN-101 and docetaxel in androgen-independent prostate cancer. Comment. Oncology Report. 2005. p. 54.
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
September 1, 2005
Issue
FALL
Start / End Page
54
Related Subject Headings
- Oncology & Carcinogenesis